Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Makers Target Children With Mucinex Mini Melts, Triaminic For Infants

This article was originally published in The Tan Sheet

Executive Summary

Several OTC manufacturers are focusing on the adolescent and children's markets with product launches planned for the 2006-2007 cough/cold season

You may also be interested in...

Triaminic Vapor Patch Adverse Events Prompt Recall By Novartis

Eight complaints of adverse health effects resulting from accidental ingestion of the Triaminic Vapor Patch have prompted a nationwide recall of products in the line by Novartis Consumer Healthcare

Adams Develops New Guaifenesin Products As Mucinex Growth Continues

Adams Respiratory Therapeutics will file an NDA before the end of the year for a product combining the firm's 12-hour extended-release guaifenesin with another respiratory ingredient to create a new, patented combination drug

Adams Brings Mucinex To Pediatric Market; Humibid Launch Slated For March

Adams Respiratory Therapeutics will launch a line of cough/cold products for children under the Mucinex brand name by the end of 2006

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts